Relationship Between Thyroid Disorders and Orbitopathy, Including Management Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Graves’ Hyperthyroidism and Graves’ Ophthalmopathy:

2005 ◽  
pp. 243-256 ◽  
Keyword(s):  
Thyroid Disorders ◽  
Graves Ophthalmopathy ◽  
Management Factors

scholarly journals Smoking and thyroid disorders--a meta-analysis

2002 ◽  
pp. 153-161 ◽  
Author(s):  
P Vestergaard
Keyword(s):  
Hashimoto’S Thyroiditis ◽  
Post Partum ◽  
Statistical Significance ◽  
Hashimoto's Thyroiditis ◽  
Graves Disease ◽  
Thyroid Disorders ◽  
Nodular Goitre ◽  
Graves Ophthalmopathy ◽  
Increased Risk ◽  
Toxic Nodular Goitre

BACKGROUND: Smoking has been associated with Graves' disease, but it remains unclear if the association is present in other thyroid disorders. OUTCOME VARIABLES: Graves' disease, Graves' ophthalmopathy, toxic nodular goitre, non-toxic goitre, post-partum thyroid disease, Hashimoto's thyroiditis, or hypothyroidism. MATERIAL AND METHODS: A search of MEDLINE identified 25 studies on the association between smoking and thyroid diseases. RESULTS: In Graves' disease eight studies were available showing an odds ratio (OR) of 3.30 (95% confidence interval (CI): 2.09-5.22) in current smokers compared with never smokers. In ex-smokers there was no significant excess risk of Graves' disease (OR=1.41, 95% CI: 0.77-2.58). The OR associated with ever smoking in Graves' ophthalmopathy (4.40, 95% CI: 2.88-6.73, six studies) was significantly higher than in Graves' disease (1.90, 95% CI: 1.42-2.55, two-sided P-value <0.01). Ever smoking was not associated with toxic nodular goitre (OR=1.27, 95% CI: 0.69-2.33, three studies), while there was an increased risk of non-toxic goitre in smokers if men were excluded (OR=1.29, 95% CI: 1.01-1.65, eight studies). The risk associated with smoking was significantly lower in men than in women for both Graves' disease and non-toxic goitre. Hashimoto's thyroiditis and post-partum thyroid dysfunction were also associated with smoking while the association with hypothyroidism did not reach statistical significance. CONCLUSIONS: Cessation of smoking seems associated with a lower risk of Graves' disease than current smoking. Smoking increases the risk of Graves' ophthalmopathy beyond the risk associated with Graves' disease alone. Smoking cessation may lead to a decrease in morbidity from Graves' disease, especially in women.

scholarly journals Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

2011 ◽  
Vol 164 (2) ◽  
pp. 303-307 ◽  
Author(s):  
Le Min ◽  
Anand Vaidya ◽  
Carolyn Becker
Keyword(s):  
Cell Activation ◽  
Immune Cell ◽  
Cytotoxic T Lymphocyte ◽  
Thyroid Autoimmunity ◽  
Angiogenesis Inhibitor ◽  
Advanced Melanoma ◽  
Thyroid Disorders ◽  
Advanced Malignancy ◽  
Immune Cell Activation ◽  
Graves Ophthalmopathy

ObjectiveIpilimumab is a fully human MAB against cytotoxic T-lymphocyte antigen 4 (CTLA4). CTLA4 negatively regulates immune cell activation. In patients with metastatic melanoma, ipilimumab increases survival time and induces complete remission in some patients. However, immune-related adverse events including endocrinopathies have been reported. Bevacizumab, an angiogenesis inhibitor, has been used in combination with ipilimumab in patients with advanced melanoma.Patients and MethodsIn this study, we report three patients who received ipilimumab alone or combined with bevacizumab therapy and developed thyroiditis, and the first report of euthyroid Graves' ophthalmopathy.ResultsCase 1 is a 51-year-old female who presented with severe eye pain, proptosis, and periorbital edema. Laboratory results revealed normal TSH, elevated thyroid antibodies but low titer of anti-TSH receptor antibody. Imaging was consistent with Graves' ophthalmopathy. Cases 2 and 3 were referred for hyperthyroidism, and workup revealed thyroiditis. These three cases suggest that patients with advanced melanoma treated with ipilimumab +/− bevacizumab may be susceptible to a variety of thyroid disorders.ConclusionsAnti-CTLA4 therapy has shown promising results in treating advanced malignancy such as melanoma and renal carcinoma. A number of endocrinopathies, including thyroid disorders, may develop during ipilimumab therapy. The association of bevacizumab with endocrinopathies is not clear, although a few reports suggest a link to hypothyroidism. All patients on ipilimumab and/or bevacizumab therapy should be monitored for signs or symptoms of thyroiditis.

Thyroglossal Duct and Ectopic Thyroid Disorders

1981 ◽  
Vol 14 (1) ◽  
pp. 187-201 ◽  
Author(s):  
Arnold M. Noyek ◽  
Jacob Friedberg
Keyword(s):  
Ectopic Thyroid ◽  
Thyroid Disorders ◽  
Thyroglossal Duct

Abstract #614 Pattern of Thyroid Disorders in Sagamu, South-West Nigeria

2019 ◽  
Vol 25 ◽  
pp. 317
Author(s):  
Ayotunde Ale ◽  
Opeyemi Aloro ◽  
Ayanbola Adepoju
Keyword(s):  
Thyroid Disorders ◽  
South West

Investigation of the Free and Total Thyroxine-binding Capacity of Plasma Proteins in Thyroid Disorders

1971 ◽  
Vol 10 (04) ◽  
pp. 299-304
Author(s):  
József Takó ◽  
János Fischer ◽  
Jusztina Juhász ◽  
Ilona Sztraka ◽  
István Kapus ◽  
...  
Keyword(s):  
Blood Cell ◽  
Thyroid Function ◽  
Oral Contraceptives ◽  
Red Blood Cell ◽  
Plasma Proteins ◽  
Binding Capacity ◽  
Thyroid Disorders ◽  
Thyroid Function Tests ◽  
Total Thyroxine

SummaryThe results of thyroid function tests have been compared with data on the thyroxine-binding capacity of plasma proteins in hyper-, hypo- and euthyroid cases, the latter including women taking oral contraceptives (Infecundin). It was found that there exists a significant correlation of exponential nature between the in vitro red blood cell 125I-triiodothyronine uptake (RCU) and the free thyroxine-binding capacity of the thyroxine-inding globulin (TBG).

TSH-Receptor autoantibodies help to predict severity and outcome of Graves' ophthalmopathy

2005 ◽  
Vol 113 (S 1) ◽  
Author(s):  
A Eckstein ◽  
M Plicht ◽  
H Lax ◽  
B Quadbeck ◽  
K Mann ◽  
...  
Keyword(s):  
Tsh Receptor ◽  
Graves Ophthalmopathy

Association between serum IGF-1 levels and thyroid disorders in a population-based study

2007 ◽  
Vol 115 (08) ◽  
Author(s):  
H Voelzke ◽  
N Friedrich ◽  
S Schipf ◽  
R Haring ◽  
J Luedemann ◽  
...  
Keyword(s):  
Population Based ◽  
Thyroid Disorders ◽  
Population Based Study

DYSLIPIDEMIA IN THYROID DISORDERS

2020 ◽  
Vol 4 (7) ◽  
Author(s):  
Kashish Narula ◽  
Narendra Kumar Dara ◽  
Shyam Lal Meena
Keyword(s):  
Lipid Metabolism ◽  
Thyroid Dysfunction ◽  
Cross Sectional Study ◽  
Control Group ◽  
Thyroid Disorders ◽  
Cross Sectional ◽  
Carbohydrate And Lipid Metabolism ◽  
History Of ◽  
Thyroid Profile ◽  
Basal Energy Expenditure

Background: Thyroid hormones influence nearly all major metabolic pathways. Their most obvious and well-known action is the increase in basal energy expenditure obtained by acting on protein, carbohydrate and lipid metabolism. The lipid metabolism is more influenced by the thyroid hormone. Methods: A cross-sectional study was conducted on 100 patients with suspicion of thyroid disorders were taken as cases. One hundred patients with normal thyroid profile and no history of other chronic diseases were taken as control group. Results: The serum TC, TG and LDL levels in hypothyroid individuals (both overt and subclinical) were significantly higher than euthyroid subjects but the levels were comparable between hyperthyroid and euthyroid group. Conclusion: Dyslipidemias are associated with thyroid disorders, so biochemical screening for thyroid dysfunction in all dyslipidemic patients. Therefore, patients presenting with dyslipidemia are recommended for investigation to explore thyroid dysfunction. Keywords: Thyroid profile, Total cholesterol, Triglycerides and LDL

Sign in / Sign up

Export Citation Format

Share Document